IgA-Nephropathie: Die häufigste Glomerulonephritis-Form

Literatur

• 1 Allen A C, Bailey E M, Brenchley P E, Buck K S, Barratt J, Feehally J. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients.  Kidney Int. 2001;  60 969-973
• 2 Ballardie F W, Roberts I S. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.  J Am Soc Nephrol. 2002;  13 142-148
• 3 D’Amico G. Clinical features and natural history in adults with IgA nephropathy.  Am J Kidney Dis. 1988;  12 353-357
• 4 Dillon J J. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability.  J Am Soc Nephrol. 1997;  8 1739-1744
• 5 Donadio J V, Bergstralh E J, Offord K P, Spencer D C, Holley K E. Mayo Nephrology Collaborative Group . A controlled trial of fish oil in IgA nephropathy.  N Engl J Med. 1994;  331 1194-1199
• 6 Donadio J V, Grande J P. IgA nephropathy.  N Engl J Med. 2002;  347 738-748
• 7 Floege J, Burg M, Kliem V. Recurrent IgA nephropathy after kidney transplantation: not a benign condition.  Nephrol Dial Transplant. 1998;  13 1933-1935
• 8 Floege J, Feehally J. IgA nephropathy: recent developments.  J Am Soc Nephrol. 2000;  11 2395-2403
• 9 Floege J, Ostendorf T. Platelet-derived growth factor: a new clinical target on the horizon.  Kidney Int. 2001;  59 1592-1593
• 10 Floege J. Evidence-based recommendations for immunosuppression in IgA-nephropathy: handle with caution.  Nephrol Dial Transplant. 2003;  18 241-245
• 11 Frimat L, Briancon S, Hestin D, Aymard B, Renoult E, Huu T C, Kessler M. IgA nephropathy: prognostic classification of end-stage renal failure.  Nephrol Dial Transplant. 1997;  12 2569-2575
• 12 Gharavi A G, Yan Y, Scolari F, Schena F P, Frasca G M, Ghiggeri G M, Cooper K, Amoroso A, Viola B F, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian B A, Wyatt R J, Lifton R P. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22 - 23.  Nat Genet. 2000;  26 354-357
• 13 Gill D G. IgA nephropathy - Henoch-Schonlein purpura - common pathogenesis (letter).  Pediatr Nephrol. 1995;  9 674
• 14 Hebert L A, Wilmer W A, Falkenhain M E, Ladson-Wofford S E, Nahman N S, Rovin B H. Renoprotection: one or many therapies?.  Kidney Int. 2001;  59 1211-1226
• 15 Ibels L S, Gyory A Z. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature.  Medicine (Baltimore). 1994;  73 79-102
• 16 Kanno Y, Okada H, Saruta T, Suzuki H. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.  Clin Nephrol. 2000;  54 360-365
• 17 Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S. Steroid therapy during the early stage of progressive IgA nephropathy: A 10-year follow-up study.  Nephron. 1996;  72 237-242
• 18 Kriz W, Gretz N, Lemley K V. Progression of glomerular diseases: is the podocyte the culprit?.  Kidney Int. 1998;  54 687-697
• 19 Nolin L, Courteau M. Management of IgA nephropathy: evidence-based recommendations.  Kidney Int Suppl. 1999;  70 S56-62
• 20 Ostendorf T, Kunter U, Groene H J, Kawachi H, Shimizu F, Koch K M, Janjic N, Floege J. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis.  J Am Soc Nephrol. 2001;  12 909-918
• 21 Peters H, Noble N A, Border W A. Transforming growth factor-beta in human glomerular injury.  Curr Opin Nephrol Hypertens. 1997;  6 389-393
• 22 Pozzi C, Bolasco P G, Fogazzi G B, Andrulli S, Altieri P, Ponticelli C, Locatelli F. Corticosteroids in IgA nephropathy: a randomised controlled trial.  Lancet. 1999;  353 883-887
• 23 Radford M G, Donadio J V, Bergstralh E J, Grande J P. Predicting renal outcome in IgA nephropathy.  J Am Soc Nephrol. 1997;  8 199-207
• 24 Rasche F M, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy.  Clin Nephrol. 1999;  51 147-152
• 25 Schena F P. A retrospective analysis of the natural history of primary IgA nephropathy worldwide.  Am J Med. 1990;  89 209-215
• 26 Schena F P, Cerullo G, Rossini M, Lanzilotta S G, D’Altri C, Manno C. Increased risk of end-stage renal disease in familial IgA nephropathy.  J Am Soc Nephrol. 2002;  13 453-460
• 27 Varis J, Rantala I, Pasternack A, Oksa H, Jantti M, Paunu E S, Pirhonen R. Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death.  J Clin Pathol. 1993;  46 607-610
• 28 Westerhuis R, Kitahara M, Daha M R, Floege J, Roos A. Interaction of MBL with IgA induces complement activation on the surface of human mesangial cells.  J Am Soc Nephrol. in Revision